The test is able to accurately select patients with early stage hormone sensitive HER2 negative breast cancer who will benefit from adjuvant chemotherapy, which encompasses approximately 15% of this population, thus sparing the remainder from unnecessary treatment [234]. This evidence concerns the gene ERBB2 and breast carcinoma.